Navigation Links
Pixantrone Shows Activity in a Preclinical Study of Experimental Autoimmune Myasthenia Gravis (EAMG)
Date:2/11/2008

Results reported in The Journal of Immunology

SEATTLE, Feb. 11 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTAX: CTIC) announced that pixantrone was shown to reduce the severity of clinical manifestation in the animal model of the autoimmune disease myasthenia gravis (MG). MG is a chronic autoimmune neuromuscular disease characterized by varying degrees of weakness of the skeletal (voluntary) muscles of the body due to autoantibodies acting against the Acethylcholine Receptor. The preclinical study was published in The Journal of Immunology (180:2696-2703, 2008) by Fulvio Baggi, M.D. and Renato Mantegazza, M.D., of the "Carlo Besta" Neurological Institute Foundation in Milan. The study compared pixantrone with the related drug, mitoxantrone, an agent currently approved to treat severe multiple sclerosis, also an autoimmune disease that attacks the central nervous system. In the current study, pixantrone was found to be more effective than mitoxantrone at improving both the laboratory and the clinical manifestations of the MG equivalent in rats. The authors concluded that "pixantrone [is] a promising immunosuppressant agent suitable for clinical investigation in myasthenia gravis, although additional experiments are needed to confirm its safety profile in prolonged treatments."

Current therapeutic treatment options for myasthenia gravis include corticosteroids and immunosuppressive drugs, both of which are effective in most patients. However, some patients do not respond to the standard treatments, and side effects may limit prolonged administration. Mitoxantrone has a broad immunosuppressive effect, but has cumulative cardiotoxicity and prolonged treatment can result in a decrease in left ventricular ejection fraction (LVEF -- the amount of blood the heart pumps out with each beat) or, rarely, congestive heart failure. Pixantrone's mechanism of action is similar to that of mitoxantrone -- both act as DNA interc
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annual Meeting
2. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
3. Novel Small Molecule Therapy Shows Benefit for Anemic Patients Via Hydration of Red Blood Cells
4. JAK2 Inhibitor Shows Potent Activity in Cells From MPD Patients
5. Newly Approved HIV Drug Shows Great Promise
6. Kaiser Permanente - Group Health Study Shows Depression Worsens HIV Treatment
7. Research Shows Decas Sweetened Dried Cranberries Pack Twice the Proanthocyanidin Punch as Cranberry Juice Cocktail
8. New Study Shows LEVITRA Successfully Treats Erectile Dysfunction (ED) in Men with Dyslipidemia, Including High Cholesterol
9. CSL Behring Study in Animal Models Shows Feasibility of Developing a Half-Life Extended Recombinant FVIIa that Retains Biologic Activity
10. Study Shows That Low-Molecular Weight Heparin (LMWH) was Associated with Reduced Hospital Costs of Venous Thromboembolism (VTE) Treatment Compared with Unfractionated Heparin (UFH)
11. Celator(R) Pharmaceuticals Reports CPX-351 Shows Anti-Cancer Activity in Leukemia Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... , July 29, 2015  Cryoport, Inc. ... "Company"), the leading provider of advanced cryogenic ... serving markets including immunotherapies, stem cells, cell ... health, and reproductive medicine, announced today that ... common stock and warrants (the "Units") under a registered ...
(Date:7/29/2015)... Colo., July 29, 2015 Heska Corporation ... a provider of advanced veterinary diagnostic and other specialty ... quarter ended June 30, 2015. Second Quarter ... Operations was up nearly 100% to $1.829 million, from $917 ... to $10.1 million, from $7.8 million. , Core Companion ...
(Date:7/29/2015)... , July 27, 2015 Research and ... of the "Global Neurostimulation Devices Market 2015" ... analysts forecast the global neurostimulation devices market to ... period 2014-2019. The report, Global Neurostimulation ... an in-depth market analysis with inputs from industry ...
Breaking Medicine Technology:Cryoport Completes $6.8 Million Equity Capital Raise 2Cryoport Completes $6.8 Million Equity Capital Raise 3Heska Reports Financial Results for the Second Quarter of 2015 2Heska Reports Financial Results for the Second Quarter of 2015 3Heska Reports Financial Results for the Second Quarter of 2015 4Heska Reports Financial Results for the Second Quarter of 2015 5Heska Reports Financial Results for the Second Quarter of 2015 6Heska Reports Financial Results for the Second Quarter of 2015 7Heska Reports Financial Results for the Second Quarter of 2015 8Global Neurostimulation Devices Market 2015-2019 2
... NEW YORK, Aug. 14 Immtech Pharmaceuticals,Inc. (Amex: ... paper published in Nucleic,Acids Research by a group ... ability of furamidine to inhibit a key enzyme ... Furamidine is the active metabolite (DB75),of Immtech,s proprietary, ...
... Scheduled Start of Phase 3 Clinical Trial, BELTSVILLE, ... has reported a second quarter 2007 loss from continuing,operations ... to a loss from,continuing operations of $699,000, or 5 ... from discontinued operations in the second quarter,of 2007 was ...
Cached Medicine Technology:Furamidine Found to Inhibit a Key Enzyme Involved in Cancer Cell DNA Repair Mechanisms 2Furamidine Found to Inhibit a Key Enzyme Involved in Cancer Cell DNA Repair Mechanisms 3Spherix Reports Second Quarter Earnings 2
(Date:7/29/2015)... ... July 29, 2015 , ... The power ... crowd-funding campaigns that give small businesses financial support, social connections can be used ... in employee health management programs, unveiled today a downloadable resource for employers that ...
(Date:7/29/2015)... FL (PRWEB) , ... July 29, 2015 , ... ... have become increasingly aware of the impact drinking and substance abuse is having ... illness. Financial loss is tagged in the billions per year. [1] Will Wesch, ...
(Date:7/29/2015)... ... 29, 2015 , ... Gender minority people who are transgender ... has provided legal protections against discrimination on the basis of gender identity in ... discrimination based on gender identity in places open to the public, such as ...
(Date:7/29/2015)... Miami, FL (PRWEB) , ... July 29, 2015 , ... ... in states where marijuana is legal, and are exposed to advertisements, for medicinal use ... University revealed teenagers in settings where the use of marijuana is considered beneficial are ...
(Date:7/29/2015)... ... 29, 2015 , ... Potomac Pilates, an elite Washington, D.C. metro area-based Pilates ... Reformer ® by Potomac Pilates. On Thursday, July 30, Potomac Pilates will unveil ... by Potomac Pilates will continue to offer the same classes and personal experiences their ...
Breaking Medicine News(10 mins):Health News:StayWell Unveils Employer Guide to Developing Effective Employee Wellness Champion Networks 2Health News:StayWell Unveils Employer Guide to Developing Effective Employee Wellness Champion Networks 3Health News:StayWell Unveils Employer Guide to Developing Effective Employee Wellness Champion Networks 4Health News:Workplace Trouble: Survey Reveals Sharp Escalation in Restaurant/Food Service Employee Drug Abuse 2Health News:Workplace Trouble: Survey Reveals Sharp Escalation in Restaurant/Food Service Employee Drug Abuse 3Health News:Fenway Health Researcher: Legal Protections in Public Settings are a Critical Public Health Issue for Transgender and Gender-Nonconforming People 2Health News:Fenway Health Researcher: Legal Protections in Public Settings are a Critical Public Health Issue for Transgender and Gender-Nonconforming People 3Health News:New Study Reveals Teens Use Marijuana More in States Where Marijuana Is Legalized 2Health News:New Study Reveals Teens Use Marijuana More in States Where Marijuana Is Legalized 3Health News:Same Great Pilates Studio, New Brand - Rock the Reformer 2
... new study to asses patient awareness of medications prescribed during ... a medication they were not, and 96% were unable to ... had been prescribed during hospitalization. These findings are published ... Inpatient medication errors represent an important patient safety issue, with ...
... , , WARRINGTON, Pa., Dec. 9 ... from nearly 600 applicants to receive part of $25,000 in PR ... it gives all of us here a warm and fuzzy feeling ... worthwhile causes," said Neotrope CEO and co-founder, Christopher L. Simmons. "We ...
... RIO DE JANEIRO, Dec. 9 Amilpar ... AMIL3.SA), the largest managed,care organization in Brazil, in addition to ... 2009, informs its shareholders and the,market that the initiatives to ... as Applicant its subsidiary AMIL ASSISTENCIA MEDICA,INTERNACIONAL LTDA. The filing ...
... Dec. 9 Kendall-Jackson Winery today sent a check ... concluding its five-month-long, online auction of items donated by ... Rachel Alexandra,s historic 2009 racing season. New items were ... item was the final lot: a visit with Rachel ...
... last year, survey shows , WEDNESDAY, Dec. 9 (HealthDay News) -- ... flu in general, there has been only a slight increase in ... a new report shows. , By the middle of November, only ... had gotten a shot, according to the survey. Seasonal flu vaccine ...
... The Michigan Minority Business Development Council (MMBDC) announced ... 29 at the Detroit Symphony Orchestra/Max Fisher Music Center, MMBDC ... for this year,s awards was: "Celebrating the Stars of ... individuals who actively include certified minority suppliers in their procurement ...
Cached Medicine News:Health News:Study highlights lack of patient knowledge regarding hospital medications 2Health News:Nonprofit Partners With PR Company and Gains International Attention 2Health News:Rachel Alexandra, Kendall-Jackson Donate $20,000 to V Foundation for Cancer Research 2Health News:Seasonal Flu Vaccination Rates Still Too Low 2Health News:Seasonal Flu Vaccination Rates Still Too Low 3Health News:Mike Lucas of GE Healthcare Recognized as the Lifeline for Minority Businesses; Receives the MMBDC 2009 President's Award 2
... Hemoglobin Testing System: The D-10 Hemoglobin ... small package. It provides a fully automated ... testing into a single platform. Programs for ... touch screen away and can be easily ...
... The ADVIA 120 Hematology System gets ... right the first time, with a ... systems. Results are more accurate, physicians ... more effective. The ADVIA 120 Hematology ...
... with the rapid, reliable test results that ... therapeutic monitoring. With the power of ... the XE-2100 offers a complete CBC with ... of NRBC, HPC and IG. Fully ...
... HmX offers three-dimensional VCS ... specificity and efficiency in ... reticulocyte analysis. With its ... dependability, HmX is an ...
Medicine Products: